A Study of the Effect of Sildenafil for Improvement of Hepatic Fibrosis after the Fontan Heart Surgery


About this study

The purpose of this study is to determine if vasodilators for the lungs can decrease liver stiffness, shown by Magnetic resonance elastography (MRE).  The study also aims to identify any clinical, laboratory, echocardiographic, imaging, and hemodynamic parameters that connect with improved outcomes of cardiac and liver status after starting the pulmonary vasodilators.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Between 18 and 80 years of age at time of heart evaluation
  • Previous surgery for single ventricle heart disease with Fontan surgical palliation
  • Put on sildenafil for pulmonary arterial hypertension

Exclusion Criteria 

  • Did not provide research authorization
  • Had a different surgical intervention other than Fontan

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Carole Warnes, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer